AQP4 and paroxysmal nocturnal hemoglobinuria: These are eculizumab, an anti-C5 antibody, approved for AQP4+ NMOSD, generalized MG, as well as atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH).